Comparing the current results to its competitors, Immuron Limited reported Revenue increase in the 4 quarter 2025 by 55.99 % year on year. The sales growth was above Immuron Limited's competitors' average revenue growth of 7.82 %, achieved in the same quarter.
Immuron Limited's Comment on Competition and Industry Peers
The company competes with pharmaceutical companies, biotechnology firms, universities, and research institutions. Competitors may develop technologies and products that could make the company's offerings obsolete or non-competitive. Many competitors possess greater financial, technical, manufacturing, and marketing resources, along with more experience in pre-clinical testing, human clinical trials, and regulatory approvals. Some competitors are developing or manufacturing technologies or products targeting the same diseases, including therapeutic approaches that directly compete with the company's product candidates.
October 4, 2024
In recent developments that underscore the intersection of innovation and global health challenges, Immuron Limited, an Australian biopharmaceutical company, has announced positive interim results following their collaboration with the US Naval Medical Research Command (NMRC) regarding a new oral therapeutic candidate aimed at infections caused by Campylobacter and Enterotoxigenic Escherichia coli (ETEC). This revelation heralds a promising step forward in tackling significant gut-mediated diseases which are prevalent in both civilian and military populations. Understanding the BackgroundCampylobacter and ETEC are recognized as leading bacterial pathogens, notorious for causing gastrointestinal infections ch...
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
Pacira Biosciences Inc is a pharmaceutical company that focuses on the development and commercialization of non-opioid pain management products and treatments.
Puma Biotechnology Inc operates as a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. Their business model revolves around identifying promising preclinical and clinical drug candidates, conducting rigorous research and development, and seeking regulatory approval for their products. Puma Biotechnology Inc strives to effectively market and distribute their approved therapeutics to provide patients with potentially life-saving treatment options.
Panbela Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative and effective treatments for pancreatic cancer. They aim to leverage their expertise in drug development and strategic partnerships to bring novel therapies to the market and address the unmet medical needs of patients with this devastating disease.
Sources:
Immuron Limited’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Immuron Limited versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
